The FDA Approval Process Needs Refinement, Not a Total Overhaul
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
Multiple Myeloma
MULTIPLE MYELOMA ADVISOR
FEATURED CONTENT
-
-
How Durable Are Responses to Targeted Therapies Across Single-Arm Cancer Trials?
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators. -
Reporting Mechanisms for Conflict of Interest Disclosures in Medicine Need Standardization
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system. -
Popular Genetic Tests Miss Many Cancer-Associated Genetic Variants, Particularly in Ethnic Minorities
The chance of missing a disease-causing variant can be as high as 100% across some groups. -
When Patient-Reported Outcomes Could Pose Risks
During a recent conference on quality of life in patients with cancer, FDA-affiliated researchers debunked a notion about biases — but raised some concerns about PROs.
VIDEO SERIES
MULTIPLE MYELOMA NEWS
Phase 2 Trial of Ibrutinib, Bortezomib, Dexamethasone Combination for R/R Multiple Myeloma Was Closed Early
Caution Urged When Considering Denosumab in Patients With Multiple Myeloma Who Have Normal Renal Function
MRD Status Assessed by Flow Cytometry Predicts Treatment Efficacy in Newly Diagnosed Multiple Myeloma
Daratumumab Increased Myeloma Patient Risk for Listeria
Inhibiting BCMA Antigen Loss May Enhance BCMA-Directed CAR-T Therapy in R/R MM
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma
